Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.
about
Lung cancer biomarkers, targeted therapies and clinical assaysRegulation of Bim in Health and DiseaseTargeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALKTherapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications.Targeting non-receptor tyrosine kinases using small molecule inhibitors: an overview of recent advances.Targeting BRAF-Mutant Non-Small Cell Lung Cancer: From Molecular Profiling to Rationally Designed Therapy.[Progress in the Treatment of Non-small Cell Lung Cancer with BRAF Inhibitors].Unlocking the Potential of High-Throughput Drug Combination Assays Using Acoustic Dispensing.MAPK activation and HRAS mutation identified in pituitary spindle cell oncocytoma.Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib.Novobiocin Analogues That Inhibit the MAPK Pathway.Understanding and targeting resistance mechanisms in NSCLC.Effects of PHA-665752 and vemurafenib combination treatment on in vitro and murine xenograft growth of human colorectal cancer cells with BRAFV600E mutations.Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors.Dabrafenib in combination with trametinib in the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer: clinical evidence and experience.Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells.Spotlight on dabrafenib/trametinib in the treatment of non-small-cell lung cancer: place in therapy.Q58736005
P2860
Q26775396-2763FCBC-BDCD-4AF9-BA1C-4D211B1215E8Q26781203-7AC9420C-1C1B-4408-98CB-39A560BB3B55Q28083446-741854B4-E147-4F21-BCC7-2B113332F7B1Q37632230-ED529323-261B-41D0-9011-7C24C25E4994Q38554422-F976EDE7-F134-4894-B44B-69EC07016E39Q39294398-1D3479ED-3B3F-44D8-939F-E3CF03E29B11Q40530427-AF4B80E5-9E7B-4725-AAC7-407AB26C7672Q40752102-9D6A26D3-2FE9-461D-AC81-310C62FD1F57Q41667684-2FA8AF80-05A0-4B39-ADB3-1C85A62D23F9Q41694346-D6CFBF74-59B9-4FB4-8609-AB5360B5D1F8Q42245370-7840F54C-2E45-4C87-A018-68F38A86DC8CQ46915997-0B35E9A3-BF6F-4B1C-8E7F-E364E4C2E8BCQ49874828-F61B9DBD-43D4-46C6-9932-DB6C4FD3351AQ49887919-711CA5C7-21C2-4560-8381-2B2EFE4EF237Q54981550-B8AC7139-56AF-4A9C-99CC-421BA3AC11BDQ55086907-B82C0122-F46C-49AE-A612-E0109F647EB7Q55279256-C210EAD7-CB0B-473B-B82E-E2C200B29E72Q58736005-CFD3BCAD-536D-4933-83FB-F2374CE73D20
P2860
Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.
@ast
Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.
@en
type
label
Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.
@ast
Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.
@en
prefLabel
Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.
@ast
Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.
@en
P2093
P2860
P1433
P1476
Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.
@en
P2093
Bruce Miller
Chandra P Belani
Monika Joshi
Shawn J Rice
P2860
P304
P356
10.1371/JOURNAL.PONE.0118210
P407
P577
2015-02-23T00:00:00Z